On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
2022 · Molecular Cancer · 53 citations
https://doi.org/10.1186/s12943-021-01479-4
X
Xingxiang Xu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
61
Papers
1.2K
Citations
15
h-index
21
i10-index
Xingxiang Xu is an academic researcher from Hanzhong People's Hospital. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & RNA modifications and cancer & Lung Cancer Research Studies. The author has an h-index of 15, co-authored 52 publications.
Papers by this author
worksRare cause of repeated pulmonary embolism: a case of primary pleural squamous cell carcinoma and literature review
2020 · BMC Pulmonary Medicine · 5 citations
https://doi.org/10.1186/s12890-020-1077-2
Texasin, A main product from Caragana Jubata (Pall.) Poir, induces proliferation arrest and protective autophagy in lung adenocarcinoma
2025 · BMC Cancer · 1 citations
https://doi.org/10.1186/s12885-025-13933-3
CircRNA protein tyrosine phosphatase receptor type a suppresses proliferation and induces apoptosis of lung adenocarcinoma cells via regulation of microRNA-582-3p
2022 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.19762452
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat